Research programme: erythropoietin long-acting - OPKO Health

Drug Profile

Research programme: erythropoietin long-acting - OPKO Health

Alternative Names: EPO-CTP; MOD-7023

Latest Information Update: 01 Sep 2013

Price : $50

At a glance

  • Originator Modigene
  • Developer OPKO Health
  • Class Erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Anaemia

Most Recent Events

  • 29 Aug 2013 PROLOR Biotech has been acquired by OPKO Health
  • 10 Jan 2013 Preclinical development is ongoing
  • 08 Jun 2010 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top